GenSight Biologics to participate in multiple upcoming investor conferences

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

GenSight Biologics Reports Interim Financial Results for the First Half of 2018

Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from REVERSE Phase III clinical trial

GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics reports €49 million cash position as of March 31, 2018 and provides update on GS010

GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Reports Full Year 2017 Financial Results

GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology